首页> 外文OA文献 >Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

【2h】

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

机译：III期，多期，随机，双盲，安慰剂控制的，对皮下信仰的104周的研究与RITUXIMAB在具有全身性狼疮红肿（SLE）的成人中（SLE）的组合给药：Bliss-right研究方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Y K Onno Teng; Ian N Bruce; Betty Diamond; Richard A Furie; Ronald F van Vollenhoven; David Gordon; James Groark; Robert B Henderson; Mary Oldham; Paul P Tak;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study [J] . Merrill J. T., van Vollenhoven R. F., Buyon J. P., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2016,第2期

机译：系统性红斑狼疮患者皮下注射talalumab（一种针对B细胞活化因子的单克隆抗体）的疗效和安全性：ILLUMINATE-2的一项52周，III期，多中心，随机，双盲，安慰剂对照研究
2. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study [J] . Isenberg D. A., Petri M., Kalunian K., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2016,第2期

机译：系统性红斑狼疮患者皮下塔巴单抗的疗效和安全性：ILLUMINATE-1的一项52周，III期，多中心，随机，双盲，安慰剂对照研究
3. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea [J] . Zhang Fengchun, Bae Sang-Cheol, Bass Damon, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第3期

机译：位于中国，日本和韩国的全身狼疮红斑狼疮患者的枢轴阶段III，随机安慰剂对照研究
4. Occupational exposure to crystalline silica and the development of systemic lupus erythematosus (SLE): A case-control study in the southeastern United States. [D] . Parks, Christine Gibson. 2001

机译：职业接触结晶二氧化硅和系统性红斑狼疮（SLE）的发展：美国东南部的病例对照研究。
5. Phase III multicentre randomised double-blind placebo-controlled 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol [O] . Y K Onno Teng, Ian N Bruce, Betty Diamond, 2019

机译：对患有系统性红斑狼疮（SLE）的成年人皮下注射贝利珠单抗联合利妥昔单抗进行的多中心随机双盲安慰剂对照的104期研究为期104周：BLISS-BELIEVE研究方案
6. LB0012 HEADLINE RESULTS FOR A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS ADVERSE EVENTS OF SPECIAL INTEREST (AESI) IN ADULTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING BELIMUMAB [O] . Saira Sheikh, Morton Scheinberg, James Cheng-Chung Wei, 2019

机译：LB0012标题结果为期4,52周，随机，双盲，安慰剂对照研究，以评估具有活性，自身抗体正系统狼疮红斑狼疮（SLE）的成人特殊兴趣（AESI）的不良事件

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

著录项

引文网络

相似文献

相关主题

期刊订阅